X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare J.B.Chemicals with Sun Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

J.B.CHEMICALS vs SUN PHARMA - Comparison Results

J.B.CHEMICALS    Change

JB Chemicals and Pharmaceuticals Limited (JBCPL), the flagship of the Unique Group, is one of the India's leading transnational pharmaceutical company. The company has 11 manufacturing facilities at four locations in India (Belapur, Ankleshwar, Panol... More

SUN PHARMA 
   Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    J.B.CHEMICALS SUN PHARMA J.B.CHEMICALS/
SUN PHARMA
 
P/E (TTM) x 17.1 35.1 48.7% View Chart
P/BV x 2.3 3.7 61.8% View Chart
Dividend Yield % 0.2 0.3 49.6%  

Financials

 J.B.CHEMICALS   SUN PHARMA
EQUITY SHARE DATA
    J.B.CHEMICALS
Mar-16
SUN PHARMA
Mar-18
J.B.CHEMICALS/
SUN PHARMA
5-Yr Chart
Click to enlarge
High Rs318701 45.4%   
Low Rs200433 46.1%   
Sales per share (Unadj.) Rs148.0110.4 134.0%  
Earnings per share (Unadj.) Rs19.111.0 173.8%  
Cash flow per share (Unadj.) Rs23.917.2 139.0%  
Dividends per share (Unadj.) Rs0.502.00 25.0%  
Dividend yield (eoy) %0.20.4 54.8%  
Book value per share (Unadj.) Rs128.9158.8 81.2%  
Shares outstanding (eoy) m84.822,399.26 3.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.75.1 34.1%   
Avg P/E ratio x13.651.6 26.3%  
P/CF ratio (eoy) x10.832.9 32.8%  
Price / Book Value ratio x2.03.6 56.2%  
Dividend payout %2.618.2 14.4%   
Avg Mkt Cap Rs m21,9511,360,021 1.6%   
No. of employees `0002.717.8 15.4%   
Total wages/salary Rs m1,84153,671 3.4%   
Avg. sales/employee Rs Th4,590.914,890.9 30.8%   
Avg. wages/employee Rs Th673.43,017.1 22.3%   
Avg. net profit/employee Rs Th592.11,480.6 40.0%   
INCOME DATA
Net Sales Rs m12,551264,895 4.7%  
Other income Rs m5428,388 6.5%   
Total revenues Rs m13,093273,282 4.8%   
Gross profit Rs m2,05556,081 3.7%  
Depreciation Rs m41214,998 2.7%   
Interest Rs m965,176 1.8%   
Profit before tax Rs m2,08844,295 4.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-9,505 0.0%   
Tax Rs m4698,452 5.6%   
Profit after tax Rs m1,61926,338 6.1%  
Gross profit margin %16.421.2 77.3%  
Effective tax rate %22.519.1 117.7%   
Net profit margin %12.99.9 129.7%  
BALANCE SHEET DATA
Current assets Rs m7,778316,359 2.5%   
Current liabilities Rs m4,358198,643 2.2%   
Net working cap to sales %27.244.4 61.3%  
Current ratio x1.81.6 112.1%  
Inventory Days Days5595 57.7%  
Debtors Days Days80108 74.3%  
Net fixed assets Rs m5,713213,178 2.7%   
Share capital Rs m1702,399 7.1%   
"Free" reserves Rs m10,547378,606 2.8%   
Net worth Rs m10,937381,006 2.9%   
Long term debt Rs m017,721 0.0%   
Total assets Rs m15,574643,028 2.4%  
Interest coverage x22.89.6 238.8%   
Debt to equity ratio x00 0.0%  
Sales to assets ratio x0.80.4 195.6%   
Return on assets %11.04.9 224.6%  
Return on equity %14.86.9 214.1%  
Return on capital %20.010.0 199.2%  
Exports to sales %48.70-   
Imports to sales %7.10-   
Exports (fob) Rs m6,115NA-   
Imports (cif) Rs m889NA-   
Fx inflow Rs m6,16940,816 15.1%   
Fx outflow Rs m1,28530,143 4.3%   
Net fx Rs m4,88410,673 45.8%   
CASH FLOW
From Operations Rs m1,39739,072 3.6%  
From Investments Rs m-320-33,708 1.0%  
From Financial Activity Rs m-1,196-15,393 7.8%  
Net Cashflow Rs m-102-7,359 1.4%  

Share Holding

Indian Promoters % 55.4 63.7 87.0%  
Foreign collaborators % 0.3 0.0 -  
Indian inst/Mut Fund % 3.4 5.1 66.1%  
FIIs % 3.9 23.0 17.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 37.0 8.3 445.8%  
Shareholders   30,437 133,026 22.9%  
Pledged promoter(s) holding % 0.0 0.5 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare J.B.CHEMICALS With:   SHASUN PHARMA  WYETH LTD  ABBOTT INDIA  UNICHEM LAB  DR. REDDYS LAB  

Compare J.B.CHEMICALS With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 383 Points Lower; Realty and Auto Stocks Drag(Closing)

After trading on a volatile note throughout the day, share markets in India witnessed selling pressure during the closing hours and ended the day in red.

Related Views on News

SUN PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Sep 19, 2018 | Updated on Sep 19, 2018

Here's an analysis of the annual report of SUN PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

SUN PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 446.1% (Quarterly Result Update)

Aug 16, 2018 | Updated on Aug 16, 2018

For the quarter ended June 2018, SUN PHARMA has posted a net profit of Rs 11 bn (up 446.1% YoY). Sales on the other hand came in at Rs 72 bn (up 16.4% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

More Views on News

Most Popular

Don't Panic in This Falling Market... Do This Instead(The 5 Minute Wrapup)

Oct 5, 2018

Find companies with long term durable moats, which are correcting with the current broader market sell-off.

Why You Should Be Excited, Not Sad, About the 30% Small Cap Crash(Profit Hunter)

Oct 4, 2018

Smallcaps have corrected over 30% since the beginning of the year. Find out why Richa Agarwal views this as an opportunity rather than a threat.

Taxpayers to pay salaries of CEOs/CIOs of Mutual Funds(The Honest Truth)

Oct 5, 2018

Ajit Dayal on the crisis in the market and in the mutual fund industry.

IPO Market Feels the Heat of the Market Crash(Sector Info)

Oct 12, 2018

The sentiments in primary market have also deteriorated amid the stock market correction. Most listed IPOs of 2018 are trading below their issue price.

Are These Deep Corrections a Buying Signal?(Chart Of The Day)

Oct 5, 2018

The correction has bought many good companies to reasonable valuations. Go against the wisdom of crowd and Buy.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

J.B.CHEMICALS SHARE PRICE


Oct 17, 2018 (Close)

TRACK J.B.CHEMICALS

  • Track your investment in J.B.CHEMICALS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

J.B.CHEMICALS - SHASUN PHARMA COMPARISON

COMPARE J.B.CHEMICALS WITH

MARKET STATS